Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting.

Lauren, Brianna; Ostvar, Sassan; Silver, Elisabeth; Ingram, Myles; Oh, Aaron; Kumble, Lindsay; Laszkowska, Monika; Chu, Jacqueline N; Hershman, Dawn L; Manji, Gulam; Neugut, Alfred I; Hur, Chin

Lauren, Brianna; Ostvar, Sassan; Silver, Elisabeth; Ingram, Myles; Oh, Aaron; Kumble, Lindsay; Laszkowska, Monika; Chu, Jacqueline N; Hershman, Dawn L; Manji, Gulam; Neugut, Alfred I; Hur, Chin.

Afiliação

Lauren B; Columbia University Medical Center, New York, NY, USA.
Ostvar S; Columbia University Medical Center, New York, NY, USA.
Silver E; Columbia University Medical Center, New York, NY, USA.
Ingram M; Columbia University Medical Center, New York, NY, USA.
Oh A; Columbia University Medical Center, New York, NY, USA.
Kumble L; Columbia University Medical Center, New York, NY, USA.
Laszkowska M; Columbia University Medical Center, New York, NY, USA.
Chu JN; Massachusetts General Hospital, Boston, MA, USA.
Hershman DL; Columbia University Medical Center, New York, NY, USA.
Manji G; Columbia University Irving Cancer Research Center, New York, NY, USA.
Neugut AI; Columbia University Medical Center, New York, NY, USA.
Hur C; Columbia University Irving Cancer Research Center, New York, NY, USA.

J Oncol ; 2020: 2198960, 2020.

Article em En | MEDLINE | ID: mdl-32148492

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: J Oncol Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google